Literature DB >> 26908751

Maternal Helminth Infection Is Associated With Higher Infant Immunoglobulin A Titers to Antigen in Orally Administered Vaccines.

Carolyn E Clark1, Michael P Fay2, Martha E Chico3, Carlos A Sandoval3, Maritza G Vaca3, Alexis Boyd1, Philip J Cooper4, Thomas B Nutman1.   

Abstract

BACKGROUND: Many studies have documented lower vaccine efficacy among children in low-income countries, compared with their counterparts in high-income countries. This disparity is especially apparent with respect to oral vaccines such as rotavirus and oral polio vaccines. One potential contributing factor is the presence of maternal antenatal helminth infections, which can modulate the infant's developing immune system.
METHODS: Using a multiplex immunoassay, we tested plasma immunoglobulin A (IgA) or immunoglobulin G (IgG) levels specific for antigens in 9 routinely administered childhood vaccines among 1639 children aged approximately 13 months enrolled in the ECUAVIDA (Ecuador Life) birth cohort study in Ecuador. We compared vaccine responses in 712 children of mothers who tested positive for helminth infections in the last trimester of pregnancy to responses in 927 children of mothers without helminth infection.
RESULTS: Plasma IgA levels specific for antigens in rotavirus vaccine and oral polio vaccine containing poliovirus serotypes 1 and 3 were all significantly higher in children of helminth-infected mothers, compared with children of uninfected mothers. Plasma IgG levels specific for diphtheria, tetanus, pertussis, measles, rubella, and Haemophilus influenzae type b vaccine antigens were comparable between the 2 groups.
CONCLUSIONS: Antenatal maternal helminth infections were not associated with reduced antibody responses to infant vaccines, but rather with modestly increased IgA responses to oral vaccines. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  IgA; helminth; immunization; maternal; vaccine

Mesh:

Substances:

Year:  2016        PMID: 26908751      PMCID: PMC4878726          DOI: 10.1093/infdis/jiw066

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

Review 1.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.

Authors:  P A Patriarca; P F Wright; T J John
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

2.  Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses.

Authors:  R L Ward; M M McNeal; J D Clemens; D A Sack; M Rao; N Huda; K Y Green; A Z Kapikian; B S Coulson; R F Bishop
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

3.  Transfer of maternal cytokines to suckling piglets: in vivo and in vitro models with implications for immunomodulation of neonatal immunity.

Authors:  Trang V Nguyen; Lijuan Yuan; Marli S P Azevedo; Kwang-Il Jeong; Ana-Maria Gonzalez; Linda J Saif
Journal:  Vet Immunol Immunopathol       Date:  2007-03-01       Impact factor: 2.046

4.  Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR.

Authors:  P J Cooper; M E Chico; G Losonsky; C Sandoval; I Espinel; R Sridhara; M Aguilar; A Guevara; R H Guderian; M M Levine; G E Griffin; T B Nutman
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

5.  In utero exposure to helminth and mycobacterial antigens generates cytokine responses similar to that observed in adults.

Authors:  I Malhotra; J Ouma; A Wamachi; J Kioko; P Mungai; A Omollo; L Elson; D Koech; J W Kazura; C L King
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

6.  Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

Authors:  H O Hallander; M Paniagua; F Espinoza; P Askelöf; E Corrales; M Ringman; J Storsaeter
Journal:  Vaccine       Date:  2002-11-22       Impact factor: 3.641

7.  Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni.

Authors:  E A Sabin; M I Araujo; E M Carvalho; E J Pearce
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

8.  A randomised controlled trial of the effects of albendazole in pregnancy on maternal responses to mycobacterial antigens and infant responses to Bacille Calmette-Guérin (BCG) immunisation [ISRCTN32849447].

Authors:  Alison M Elliott; Proscovia B Namujju; Patrice A Mawa; Maria A Quigley; Margaret Nampijja; Peter M Nkurunziza; John T Belisle; Moses Muwanga; James A G Whitworth
Journal:  BMC Infect Dis       Date:  2005-12-21       Impact factor: 3.090

9.  Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya.

Authors:  Indu Malhotra; Maxim McKibben; Peter Mungai; Elisabeth McKibben; Xuelei Wang; Laura J Sutherland; Eric M Muchiri; Charles H King; Christopher L King; A Desiree LaBeaud
Journal:  PLoS Negl Trop Dis       Date:  2015-01-15

10.  Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A.

Authors:  T Defrance; B Vanbervliet; F Brière; I Durand; F Rousset; J Banchereau
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  9 in total

1.  Redirecting reproductive immunology research toward pregnancy as a period of temporary immune tolerance.

Authors:  Norbert Gleicher; Vitaly A Kushnir; David H Barad
Journal:  J Assist Reprod Genet       Date:  2017-02-10       Impact factor: 3.412

Review 2.  Immunity to enteric viruses.

Authors:  Ainsley Lockhart; Daniel Mucida; Roham Parsa
Journal:  Immunity       Date:  2022-05-10       Impact factor: 43.474

Review 3.  Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.

Authors:  Daniel E Velasquez; Umesh Parashar; Baoming Jiang
Journal:  Expert Rev Vaccines       Date:  2017-12-29       Impact factor: 5.217

4.  The impact of prenatal exposure to parasitic infections and to anthelminthic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial.

Authors:  Stephen Nash; Alexander J Mentzer; Swaib A Lule; Dennison Kizito; Gaby Smits; Fiona R M van der Klis; Alison M Elliott
Journal:  PLoS Negl Trop Dis       Date:  2017-02-08

Review 5.  A life without worms.

Authors:  Richard E Sanya; Gyaviira Nkurunungi; Irene Andia Biraro; Harriet Mpairwe; Alison M Elliott
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-01-01       Impact factor: 2.184

6.  Urban-rural differences in immune responses to mycobacterial and tetanus vaccine antigens in a tropical setting: A role for helminths?

Authors:  Joyce Kabagenyi; Agnes Natukunda; Jacent Nassuuna; Richard E Sanya; Margaret Nampijja; Emily L Webb; Alison M Elliott; Gyaviira Nkurunungi
Journal:  Parasitol Int       Date:  2020-05-05       Impact factor: 2.230

7.  Plasmodium and intestinal parasite perturbations of the infected host's inflammatory responses: a systematic review.

Authors:  Aminata Colle Lo; Babacar Faye; Ben Adu Gyan; Linda Eva Amoah
Journal:  Parasit Vectors       Date:  2018-07-03       Impact factor: 3.876

Review 8.  The effect of helminth infection on vaccine responses in humans and animal models: A systematic review and meta-analysis.

Authors:  Agnes Natukunda; Ludoviko Zirimenya; Jacent Nassuuna; Gyaviira Nkurunungi; Stephen Cose; Alison M Elliott; Emily L Webb
Journal:  Parasite Immunol       Date:  2022-07-05       Impact factor: 2.206

Review 9.  Causes of impaired oral vaccine efficacy in developing countries.

Authors:  Edward Pk Parker; Sasirekha Ramani; Benjamin A Lopman; James A Church; Miren Iturriza-Gómara; Andrew J Prendergast; Nicholas C Grassly
Journal:  Future Microbiol       Date:  2017-12-08       Impact factor: 3.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.